<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00179777</url>
  </required_header>
  <id_info>
    <org_study_id>MCT-49395</org_study_id>
    <secondary_id>U01HD040364</secondary_id>
    <secondary_id>U01HD042444</secondary_id>
    <nct_id>NCT00179777</nct_id>
  </id_info>
  <brief_title>TRIGR - Primary Prevention Study for Type 1 Diabetes in Children at Risk</brief_title>
  <official_title>TRIGR - Trial to Reduce IDDM in the Genetically at Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Eastern Ontario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>US Congress</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Foundation for the Study of Diabetes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Community (EC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mead Johnson Nutrition</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diabetes Research Foundation, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dutch Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital of Eastern Ontario</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Trial to Reduce IDDM in the Genetically at Risk (TRIGR) is an international effort to
      conduct a primary prevention nutrition trial for type 1 (insulin-dependent) diabetes. The
      TRIGR study is targeted at newborns who are at genetic risk for type 1 diabetes because their
      mother, father and/or full sibling has type 1 diabetes. All families are encouraged to breast
      feed their infants for as long as possible. Prior to birth, the child is randomly assigned to
      receive one of two infant formulas, should formula be required prior to 8 months of age. The
      study will determine whether weaning to a possibly protective infant formula decreases these
      children's chances of developing diabetes - as it does in the animal models for diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis for this study is that weaning to an extensively hydrolyzed infant formula
      will decrease the incidence of type 1 diabetes in subjects with risk-associated HLA genotypes
      and a first degree relative with type 1 diabetes, as it does in all relevant animal models
      for the disease.

      Specific Aims:

      I.a: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of
      diabetes-predictive auto-antibodies in subjects with risk-associated HLA genotype and a first
      degree relative with type 1 diabetes (mother, father and/or full sibling).

      I-b: To determine if weaning to a casein hydrolysate infant formula reduces the frequency of
      clinical diabetes in subjects with risk-associated HLA genotype and an affected first degree
      relative.

      A secondary aim is to determine relationships between cow's milk antibodies, a measure of
      cow's milk exposure, and diabetes-associated auto-antibodies.

      The mother of the unborn child is recruited during pregnancy. Randomization to one of two
      infant formulas takes place before birth (after 35 weeks gestation) or immediately after
      birth.

      Experimental Arm: Use of extensively hydrolysed cow's milk based infant formula when needed
      in supplementation or substitution for breast milk through 6-8 months from birth.

      Control Arm: Use of non-hydrolysed cow's milk based infant formula when needed in
      supplementation or substitution for breast milk through 6-8 months from birth.

      All families are encouraged to breast feed their infants for as long as possible. The study
      infant formula is only used if exclusive breast feeding ceases before 8 months of age.

      Cord blood for genotyping is obtained at birth, or failing that from a heel prick by 7 days
      of age. Only subjects with genotypes indicating increased genetic risk for type 1 diabetes
      remain in the intervention trial. All other subjects are withdrawn from the study.

      All subjects will be followed until the youngest subject turns age 10 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2002</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type 1 diabetes mellitus assessed by (1) blood glucose and HbA1c at 12 and 18 months of age, and annually from age 2 to 10 years, and (2) oral glucose tolerance test at 6 and 10 years of age.</measure>
    <time_frame>12 and 18 months and annually from 2 years up to 15 years</time_frame>
    <description>glucose and HbA1C; oral glucose tolerance test at 6, 10 years and in the final year of the study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diabetes associated islet antibodies (ICA, IAA, GADA, IA-2A) at 3, 6, 9, 12 and 18 months of age, and annually from age 2 to 10 years</measure>
    <time_frame>3, 6, 9, 12, 18 months and annually from 2 years up to 15 years</time_frame>
    <description>diabetes associated antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2032</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Hydrolysed infant formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydrolysed infant formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonhydrolysed infant formula</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nonhydrolysed infant formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>hydrolysed infant formula</intervention_name>
    <description>hydrolysed infant formula</description>
    <arm_group_label>Hydrolysed infant formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>nonhydrolysed infant formula</intervention_name>
    <description>nonhydrolysed infant formula</description>
    <arm_group_label>Nonhydrolysed infant formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biological parent and/or full (not half) sibling of the newborn infant has type 1
             diabetes as defined by the World Health Organization

          -  The infant's parent or legal guardians give signed consent to participate

        Exclusion Criteria:

          -  An older sibling of the newborn infant has been included in the TRIGR intervention

          -  Multiple gestation

          -  The parents are unwilling or unable to feed the infant cow's milk based products for
             any reason (e.g., religious, cultural).

          -  The newborn infant has a recognizable severe illness such as those due to chromosomal
             abnormality, congenital malformation, respiratory failure needing assisted
             ventilation, enzyme deficiencies, etc.

          -  The gestational age of the newborn infant is less than 35 weeks.

          -  The infant is older than 7 days at randomization.

          -  Inability of the family to take part in the study (e.g. the family has no access to
             any of the Study Centers, the family has no telephone).

          -  The infant has received any infant formula other than Nutramigen prior to
             randomization.

          -  No HLA sample drawn before the age of 8 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans K Akerblom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-2583</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robarts Research Institute</name>
      <address>
        <city>London</city>
        <zip>N6A 5K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3rd Faculty of Medicine, Charles University, University Hospital Vinohrady</name>
      <address>
        <city>Prague</city>
        <zip>10</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tartu University Children's Hospital</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Helsinki</name>
      <address>
        <city>Helsinki</city>
        <zip>00029HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderkrankenhaus auf der Bult</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Medical University</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michele Hospital</name>
      <address>
        <city>Cagliari</city>
        <state>Sardinia</state>
        <zip>09134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Campus Bio-Medico of Rome</name>
      <address>
        <city>Rome</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Luxembourg</name>
      <address>
        <city>Luxembourg</city>
        <zip>1210</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Wroclaw</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-376</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Vizcaya</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Linkoping</name>
      <address>
        <city>Linkoping</city>
        <zip>S-58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Luxembourg</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.trigr.org</url>
    <description>TRIGR International website - Click here for more information on this study - www.TRIGR.org</description>
  </link>
  <link>
    <url>http://www.trigrnorthamerica.com</url>
    <description>TRIGR North America website - Click here for more information on this study - www.trigrnorthamerica.org</description>
  </link>
  <reference>
    <citation>Akerblom HK, Virtanen SM, Ilonen J, Savilahti E, Vaarala O, Reunanen A, Teramo K, Hämäläinen AM, Paronen J, Riikjärv MA, Ormisson A, Ludvigsson J, Dosch HM, Hakulinen T, Knip M; National TRIGR Study Groups. Dietary manipulation of beta cell autoimmunity in infants at increased risk of type 1 diabetes: a pilot study. Diabetologia. 2005 May;48(5):829-37. Epub 2005 Apr 19. Erratum in: Diabetologia. 2005 Aug;48(8):1676. Riikjärv, MA [added]; Ormisson, A [added]; Ludvigsson, J [added]; Dosch, HM [added]; Hakulinen, T [added]; Knip, M [added].</citation>
    <PMID>15838685</PMID>
  </reference>
  <reference>
    <citation>TRIGR Study Group. Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR). Pediatr Diabetes. 2007 Jun;8(3):117-37.</citation>
    <PMID>17550422</PMID>
  </reference>
  <reference>
    <citation>Åkerblom HK, Knip M, Becker D, Dosch H-M, Dupré J, Ilonen J, Krischer JP and the TRIGR Study Group. The TRIGR Trial: Testing the Potential Link between Weaning Diet and Type 1 Diabetes. Immun, Endoc, Metab Agents in Med Chem 7:251-263, 2007.</citation>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Eastern Ontario</investigator_affiliation>
    <investigator_full_name>Margaret Lawson</investigator_full_name>
    <investigator_title>Site Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Genetic Predisposition to Disease</keyword>
  <keyword>Infant Nutrition</keyword>
  <keyword>Primary Prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

